Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.
Namisaki T, Moriya K, Kitade M, Kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanishi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H. Namisaki T, et al. Among authors: saikawa s. Eur J Gastroenterol Hepatol. 2017 Jan;29(1):23-30. doi: 10.1097/MEG.0000000000000765. Eur J Gastroenterol Hepatol. 2017. PMID: 27755231
von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.
Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. Takaya H, et al. Among authors: saikawa s. United European Gastroenterol J. 2018 Nov;6(9):1401-1409. doi: 10.1177/2050640618779660. Epub 2018 May 25. United European Gastroenterol J. 2018. PMID: 30386613 Free PMC article.
Identification of clinical risk factors for histological progression of primary biliary cholangitis.
Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H. Fujinaga Y, et al. Among authors: saikawa s. Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14. Hepatol Res. 2019. PMID: 31021038
Effect of furosemide on muscle cramps in patients with liver cirrhosis.
Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Takaya H, Kaji K, Shimozato N, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Sawada Y, et al. Among authors: saikawa s. J Gastroenterol Hepatol. 2020 Jan;35(1):76-81. doi: 10.1111/jgh.14820. Epub 2019 Aug 16. J Gastroenterol Hepatol. 2020. PMID: 31385352
Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.
Moriya K, Namisaki T, Sato S, Furukawa M, Douhara A, Kawaratani H, Kaji K, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Yoshiji H. Moriya K, et al. Among authors: saikawa s. Clin Mol Hepatol. 2019 Dec;25(4):381-389. doi: 10.3350/cmh.2019.0037. Epub 2019 Aug 13. Clin Mol Hepatol. 2019. PMID: 31405269 Free PMC article.
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.
Furukawa M, Moriya K, Nakayama J, Inoue T, Momoda R, Kawaratani H, Namisaki T, Sato S, Douhara A, Kaji K, Kitade M, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Tanaka Y, Yoshiji H. Furukawa M, et al. Among authors: saikawa s. Hepatol Res. 2020 Jul;50(7):840-852. doi: 10.1111/hepr.13509. Epub 2020 Jun 10. Hepatol Res. 2020. PMID: 32346970
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Okura Y, Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Noguchi R, Nishimura N, Seki K, Kawaratani H, Takaya H, Sato S, Sawada Y, Shimozato N, Furukawa M, Nakanishi K, Saikawa S, Kubo T, Asada K, Yoshiji H. Okura Y, et al. Among authors: saikawa s. Hepatol Res. 2017 Nov;47(12):1317-1328. doi: 10.1111/hepr.12860. Epub 2017 Feb 13. Hepatol Res. 2017. PMID: 28029729
Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization.
Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Yoshiji H. Douhara A, et al. Among authors: saikawa s. Oncol Lett. 2017 Sep;14(3):3028-3034. doi: 10.3892/ol.2017.6489. Epub 2017 Jun 28. Oncol Lett. 2017. PMID: 28927051 Free PMC article.
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.
Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Fujinaga Y, Yoshiji H. Namisaki T, et al. Among authors: saikawa s. Hepatol Commun. 2017 Sep 19;1(9):928-945. doi: 10.1002/hep4.1104. eCollection 2017 Nov. Hepatol Commun. 2017. PMID: 29404501 Free PMC article.
59 results